Samsca is an oral drug owned by Otsuka. Active ingredient in Samsca is tolvaptan. It was first authorized for market use on 19 May, 2009. The drug is available in tablet form.
The generic version of Samsca is possible to be released after 07 April, 2030. This is because the last patent of Samsca, US10905694 titled 'Pharmaceutical solid preparation comprising benzazepines and production method thereof', is set to expire on this date.
Samsca uses the active ingredient tolvaptan, which helps to correct a certain type of hormone imbalance and improve low sodium levels in the body.
Samsca holds two patents. Out of these, US8501730 titled 'Process for preparing benzazepine compounds or salts thereof' will expire on 01 September, 2026 and the patent US10905694 will expire on 07 April, 2030. Below are the details of the patent: